Cannabis Science (OTCMKTS:CBIS) put out its guidance for the new year on January 5, stating that it is starting out the new year healthier than ever before.
The company is focused on the development of cannabis-based medicines, with an initial focus on skin cancers, HIV/AIDS and neurological conditions, and says that it has placed a heavy emphasis on accelerating its pharmaceutical drug development programs. Its main goal is to acquire national and international regulatory approval for its cannabis-based formulations.
“2015 was a great year of growth for our Company. We made a great deal of progress with our drug development, acquisition strategy, product roll out, and strategic partnership search,” said company President and CEO Raymond Dabney in a statement. “With that said, 2016 is looking to be an exciting year for Cannabis Science. We are kicking off the new year with new products already brought to market — a huge head start over last year.”
In mid-December, the company secured a drug development agreement for CS-NEURO-1, a step toward starting phase 1 human clinical trials in Europe. Then, in November, Cannabis Science launched its cannabinoid-formulated capsule product line in California; back in May, it acquired pet care manufacturer and distributor Equi-Pharm with a view to entering the pet care industry.


However, it’s worth noting that the Cannabis Science stock price has fallen over 80 percent in the past year, and is currently trading just above a penny. In fact, aside from a small share price spike last August, shares of the company remained steadily on the downtrend for the entire year — and so far in 2016, the Cannabis Science stock price is down 12 percent.
Diane Alter at Money Morning offered some insight into the company’s situation back in May. “The Colorado Springs, Colo.-headquartered company maintains its immediate focus is to treat cancer,” she said. “Its main focus, however, should be its massive cash burn.”
Alter explained that the company had just $10,000 in cash, as per its annual report released in April, and that Cannabis Science had reported assets worth $166,000 compared to liabilities of about $3.96 million.
Taking a look at the company’s most recent report for the quarter ended September 30, the situation hasn’t improved much. Cannabis Science had $4,791 in cash, $138,000 in assets and $5.1 million in liabilities. Revenues came in at $4,150, but the company also recorded a $3.9-million net loss.

However, despite those numbers, one analyst still appears to be positive on the company. On Novemeber 24, Cannabis Science shared an independent analyst report from Charles Reed of Caprock Research; in it, the firm gives Cannabis Science an ‘Accumulate’ recommendation, a near-term share price target of $0.05 and a long-term target of $0.10.
In the 33-page report, the Reed admits that Cannabis Science stock has been under significant pressure, but states that the company appears to have a “first mover” advantage in terms of targeting particular applications for cannabinoids. The report was disseminated via Wall Street Corner.
To be sure, Cannabis Science is still a long way off from reaching the price targets mentioned above, and its balance sheet isn’t so healthy. Still, interested investors will no doubt be standing by for updates.
The Cannabis Science stock price is currently sitting at $0.0132. It has traded within a 52-week range of $0.01 to $0.07, with an average daily trading volume of 6.76 million shares. The company has a market capitalization of 17.19 million.
 
Securities Disclosure: I, Teresa Matich, hold no direct investment interest in any company mentioned in this article.

 BioHarvest Sciences Inc. (CSE: BHSC) (the “Company” or “BioHarvest”) invites its shareholders and the general public to join a Live Video Conference (“Webinar”) on Thursday, January 21st, 2021 at 2:00 PM Eastern Standard Time (11:00 AM Pacific Standard Time). Ilan Sobel, CEO of BHSC, will host the event and discuss progress on Bioharvest’s Growth Plan, which will include highlights of the 2020 milestones achieved, key business capabilities built, and will provide an important overview of 2021 Priorities.

The presentation will be approximately 35 minutes, followed by a live question and answer session.

Keep reading... Show less

World-Class Extractions Inc. (CSE:PUMP)(FRA:WCF)(OTCQB:WCEXF) (the “Company” or “World-Class”), reports that it has sold its 50% interest in Cobra Ventures Inc. (“Cobra”), which sale included all funds previously advanced by World Class to Cobra, to the remaining shareholder of Cobra, for $2,500,000 in cash

An investment group led by Richard Goldstein retains 100% control of Cobra, and its senior secured debenture of Hydrx Farms Ltd. (“Hydrx”), acquired by Cobra in October 2020.

Keep reading... Show less

Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos Group” or the “Company”), an innovative global cannabinoid company, today announced that Kurt Schmidt, President and Chief Executive Officer, will speak at the 24th Annual CIBC Western Institutional Investor Conference on Friday, January 22, 2021 at 4:10 p.m. EST.

A recording will be available on the Investors section of the Company’s website at https://ir.thecronosgroup.com/events-presentations .

Keep reading... Show less
  • Disease control of root-rot Aphanomyces zoospores in laboratory tests.
  • Outstanding Efficacy: 100% control at economic application rates within 24 hours.
  • Aphanomyces is a soil-borne root-rot disease that destroys peas, lentils, and legume crops.

MustGrow Biologics Corp. (CSE: MGRO) (OTC: MGROF) (FSE: 0C0) (the “Company”, “MustGrow”) is pleased to announce successful laboratory test results of its patented mustard-derived biopesticide on Aphanomyces euteiches zoospores (“Aphanomyces”) via an independent third party facility: 100% control at economic application rates within 24 hours. MustGrow will now advance to larger scale greenhouse and field tests. Study results and applicability are patent-protected under MustGrow’s existing suite of issued patents.

MustGrow’s remarkably safe and effective organic biopesticide is plant-based – harnessing the mustard seed’s natural defense mechanism to control diseases, pests, and weeds with an organic food-grade biopesticide.

Keep reading... Show less

Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco” or “the Company”), one of the largest vertically integrated multistate cannabis operators in the United States, announced the hiring of CPG industry veteran Ty Gent as the Company’s new Chief Operating Officer (“COO”). As COO, Gent will be responsible for operational consistency and efficiency across markets and implementation of structural enhancements to facilitate scaling.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210119005322/en/

Keep reading... Show less